ExpressPoints: Educating Providers and Patients to Optimize the Use of Targeted Oral Therapies for HR+/HER2- Breast Cancer

Gain key clinical insights fast, with this short slideset from CCO on the optimal use of CDK4/6 and PIK3CA inhibitors for patients with HR+/HER2 breast cancer.  

Matthew P. Goetz, MD
Sara Hurvitz, MD, FACP
Joyce O'Shaughnessy, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 603 KB
Released: March 9, 2021

Acknowledgements

Produced in collaboration with
Supported by an educational grant from
Lilly

Related Content

Prof. Dr. Arndt Hartmann Released: April 9, 2021

Expert faculty review the use of targeted oral therapies for HR+/HER2- breast cancer in a webcast presented by Clinical Care Options (CCO)

Matthew P. Goetz, MD Sara Hurvitz, MD, FACP Joyce O'Shaughnessy, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: April 8, 2021 Expired: April 7, 2022

Experts discuss their practices with CDK4/6 and PI3K inhibitors for patients with breast cancer in today’s clinic from Clinical Care Options (CCO)

Matthew P. Goetz, MD Sara Hurvitz, MD, FACP Joyce O'Shaughnessy, MD Released: March 23, 2021

Expert commentary with a European perspective on key studies from 2020 SABCS, from Clinical Care Options (CCO)

Javier Cortes, MD, PhD Released: March 8, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue